{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-054736","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2026-05-12T11:51:50+00:00","discovered_at":"2026-05-12T11:55:00.293820+00:00","generated_at":"2026-05-12T11:55:24.921409+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026","bullets":["Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.","Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.","FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.","R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.","Commercial readiness activities ongoing for potential OLC launch after PDUFA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054736","json":"https://secwatch.observer/filing/0001213900-26-054736.json","markdown":"https://secwatch.observer/filing/0001213900-26-054736.md","text":"https://secwatch.observer/filing/0001213900-26-054736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/0001213900-26-054736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea0290277-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:55:24.921409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e07f1f01e72fb03ae013f90ed0ad789b34a0ea80","claim":"Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $(12.8) million loss, EPS $(0.54) per share of common stock.","evidence_excerpt":"Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/0001213900-26-054736-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$(12.8) million loss"},{"label":"EPS","value":"$(0.54) per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}